Organigram Global (OGI) Common Equity (2018 - 2026)

Organigram Global (OGI) reported Common Equity of $271.1 million for Q1 2026, up 2.34% quarter-over-quarter from $264.9 million in Q4 2025.

Organigram Global (OGI) Common Equity (2018 - 2026) Analysis & Trends

Organigram Global (OGI) has 6 years of Common Equity data on file, last reported at $271.1 million in Q1 2026.

Common Equity for Q1 2026 came in at $271.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $271.1 million (changed N/A YoY), and the FY2025 annual result was $264.9 million, changed N/A from the prior year.
Common Equity climbed to $271.1 million in Q1 2026 per OGI's latest filing, from $264.9 million in the prior quarter.
Over five years, Common Equity peaked at $271.1 million in Q1 2026 and troughed at $253.7 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Common Equity (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	8.23 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	3.23 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	5.90 Bn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	407.18 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	3.41 Bn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	6.50 Bn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	1.75 Bn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	446.17 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	1.21 Bn
10	Organigram Global	731.20 Mn	673.26 Mn	11.96 Mn	271.13 Mn

Download Data